Skip to content

Study to evaluate the Efficacy of Study Product of Carica papaya leaf Extract and Tinospora cardifolia Extract in the Cancer Patients

A Post marketing Randomized Placebo Controlled Study to evaluate the Efficacy of Study Product UPLAT (Carica papaya leaf Extract Tinospora cardifolia Extract) in the Cancer Patients with Thrombocytopenia induced by Chemotherapy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012064
Enrollment
60
Registered
2018-02-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Thrombocytopenia induced by Chemotherapy

Interventions

Intervention1: UPLAT: Carica papaya leaf Extract ,Tinospora cardifolia Extract. UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract) is an orally administered product for management o

Sponsors

Sanat Products Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female aged between 18-55 years. 2. Subjects must sign with date an informed consent prior to any evaluation and participation in the trial. 3. Patients who were confirmed solid tumour and received at least one cycle of chemotherapy prior to screening visit. 4. Patients with a platelet counts between > 20000 and

Exclusion criteria

Exclusion criteria: 1. Planning to receive any type of surgery. 2. Pregnant or lactating women. 3. Patients with platelet count less than 20000/ml. 4. Patients with thrombocytopenia presenting with active bleeding. 5. Patients who have received blood or blood product transfusion during the current illness or during past one week. 6. Patients with thrombocytopenia purpura (ITP) leukemia, hemophilia or bleeding diathesis. 7. Participation in another trial with another investigational product.

Design outcomes

Primary

MeasureTime frame
Increase in the platelet counts from baseline levels to the end of therapy.Timepoint: Day 0 to Day 15

Secondary

MeasureTime frame
Safety of Study DrugTimepoint: Day 15

Countries

India

Contacts

Public ContactAjeet Nanda

Socrates School Of Health

Kumar.Ajeet10101981@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026